We are live on !
Find out more
Stempoint Capital Portfolio holdings
AUM
$581M
Turnover
56.9%
1-Year Est. Return
373.68%
This Fund
S&P 500
This Quarter Est. Return
+8.95%
1 Year Est. Return
+373.68%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$312M
AUM Growth
-$2.13M
(-0.68%)
Cap. Flow
-$12.8M
Cap. Flow % of AUM
Cap. Flow %
-4.11%
Top 10 Holdings %
Top 10 Hldgs %
50%
Holding
82
New
21
Increased
16
Reduced
15
Closed
29
Avg Time Held
Equity + Options
0.5
years
Top 10 Avg Time Held
Equity + Options
0.5
years
Top 20 Avg Time Held
Equity + Options
0.5
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mineralys Therapeutics
MLYS
|
+$9.15M |
| 2 |
Legend Biotech
LEGN
|
+$8.75M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
+$8.75M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
+$8.52M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$8.52M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Roivant Sciences
ROIV
|
+$21.4M |
| 2 |
Revolution Medicines
RVMD
|
+$11.3M |
| 3 |
Nuvalent
NUVL
|
+$9.6M |
| 4 |
Xenon Pharmaceuticals
XENE
|
+$9.21M |
| 5 |
CG Oncology
CGON
|
+$7.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.17% |
| 2 | Financials | 0.51% |
| 3 | Miscellaneous | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Syndax Pharmaceuticals
SNDX
$860M
| $22.2M | 7.13% |
2,372,634
+774,040
| +48% | +$8.52M |
2023 Q4
6 quarters
|
|
2
Immunovant
IMVT
$7.27B
| $20.8M | 6.68% |
1,300,860
+447,388
| +52% | +$6.77M |
2023 Q4
6 quarters
|
|
3
Scholar Rock
SRRK
$6.28B
| $18.7M | 6% |
528,115
-38,097
| -7% | -$1.2M |
2024 Q4
2 quarters
|
|
|
CNTA
4
DELISTED
Centessa Pharmaceuticals
CNTA
| $16.6M | 5.34% |
1,265,672
+672,337
| +113% | +$8.52M |
2024 Q3
3 quarters
|
|
5
Madrigal Pharmaceuticals
MDGL
$10.1B
| $15.9M | 5.12% |
52,694
+11,758
| +29% | +$3.5M |
2025 Q1
1 quarter
|
|
6
DELISTED
Merus
MRUS
| $14M | 4.49% |
266,094
-80,662
| -23% | -$3.79M |
2023 Q4
6 quarters
|
|
7
DELISTED
Arcellx
ACLX
| $13.3M | 4.26% |
201,452
-72,322
| -26% | -$4.5M |
2025 Q1
1 quarter
|
|
8
DELISTED
Cidara Therapeutics
CDTX
| $13M | 4.17% |
+266,774
| New | +$6.41M |
2025 Q2
0 quarters
|
|
|
9
Rhythm Pharmaceuticals
RYTM
$7.9B
| $11.2M | 3.58% |
176,752
+142,936
| +423% | +$8.75M |
2024 Q3
3 quarters
|
|
10
Alkermes
ALKS
$7.76B
| $10M | 3.22% |
351,124
+158,772
| +83% | +$4.73M |
2024 Q3
3 quarters
|
|
11
Denali Therapeutics
DNLI
$3.18B
| $9.9M | 3.18% |
707,915
+40,837
| +6% | +$575K |
2024 Q2
4 quarters
|
|
|
12
Legend Biotech
LEGN
$3.97B
| $9.6M | 3.08% |
+270,144
| New | +$8.75M |
2025 Q2
0 quarters
|
|
13
Geron
GERN
$642M
| $9.38M | 3.01% |
6,649,244
+5,688,937
| +592% | +$8.06M |
2025 Q1
1 quarter
|
|
14
Zai Lab
ZLAB
$3.32B
| $8.76M | 2.81% |
250,438
+224,017
| +848% | +$7.37M |
2025 Q1
1 quarter
|
|
|
15
Mineralys Therapeutics
MLYS
$1.4B
| $8.55M | 2.74% |
+631,586
| New | +$9.15M |
2025 Q2
0 quarters
|
|
16
uniQure
QURE
$1.6B
| $7.98M | 2.56% |
572,615
-158,424
| -22% | -$2.13M |
2024 Q4
2 quarters
|
|
|
17
Roivant Sciences
ROIV
$29.8B
| $6.78M | 2.18% |
601,781
-1,977,079
| -77% | -$21.4M |
2023 Q4
6 quarters
|
|
18
DELISTED
Akero Therapeutics
AKRO
| $6.23M | 2% |
116,779
-39,406
| -25% | -$1.79M |
2025 Q1
1 quarter
|
|
19
Insmed
INSM
$25.5B
| $6.2M | 1.99% |
61,578
-25,481
| -29% | -$1.95M |
2024 Q4
2 quarters
|
|
20
Surrozen
SRZN
$376M
| $6.14M | 1.97% |
686,539
+445,713
| +185% | +$4.07M |
2024 Q2
4 quarters
|
|
21
Wave Life Sciences
WVE
$686M
| $5.85M | 1.88% |
900,338
+810,505
| +902% | +$5.35M |
2024 Q3
3 quarters
|
|
22
LENZ Therapeutics
LENZ
$135M
| $5.39M | 1.73% |
+183,912
| New | +$5M |
2025 Q2
0 quarters
|
|
|
23
DELISTED
Nuvalent
NUVL
| $4.56M | 1.47% |
59,828
-130,573
| -69% | -$9.6M |
2024 Q4
2 quarters
|
|
24
DELISTED
KalVista Pharmaceuticals
KALV
| $4.37M | 1.4% |
386,790
-47
| -0% | -$575 |
2024 Q4
2 quarters
|
|
25
VistaGen Therapeutics
VTGN
$8.13M
| $4.12M | 1.32% |
2,413,254
+46,700
| +2% | +$106K |
2023 Q4
6 quarters
|
|
Similar funds
GFI
CTAF
Stempoint Capital's Q2 2025 Portfolio in Review
As of Q2 2025, Stempoint Capital held 82 positions worth $312M, down 0.68% from $314M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Stempoint Capital withdrew a net $12.8M in Q2 2025, closing 29 positions and reducing 15 holdings. Its most notable exit was Revolution Medicines, an estimated $11.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.
Against the trend, Stempoint Capital opened a new position in Mineralys Therapeutics worth $8.55M.
- Stempoint Capital's largest Q2 2025 buy was Mineralys Therapeutics: 631,586 shares worth $8.55M.
- Stempoint Capital added most to Rhythm Pharmaceuticals in Q2 2025, an estimated $8.75M increase.
- Stempoint Capital's biggest Q2 2025 reduction was Roivant Sciences, cutting an estimated $21.4M.
- Stempoint Capital fully exited Revolution Medicines in Q2 2025, selling an estimated $11.3M.
- Stempoint Capital's ten largest holdings make up 50% of its $312M portfolio in Q2 2025.
- Stempoint Capital opened 21 new positions and closed 29 in Q2 2025.
- Stempoint Capital's portfolio value fell 0.68% quarter-over-quarter to $312M.
Based on Stempoint Capital's 13F filing for Q2 2025, filed 14 Aug 2025.